United Homes Group stock plunges after Nikki Haley, directors resign
Jennifer Taubert, Executive Vice President at Johnson & Johnson (NYSE:JNJ), sold 56,471 shares of common stock on September 4, 2025. The shares were sold at a weighted average price of $177.806, resulting in a total transaction value of $10,040,882. The prices for the sale ranged from $177.715 to $177.89.
On the same day, Taubert also exercised options to acquire 56,471 shares of Johnson & Johnson common stock at a price of $101.87 per share, for a total value of $5,752,700.
Following these transactions, Taubert directly owns 178,013.001 shares of Johnson & Johnson.
In other recent news, Johnson & Johnson reported strong financial results for the second quarter of 2025, with worldwide sales reaching $23.7 billion, representing a 4.6% operational sales growth. The company has also raised its full-year sales guidance to $92.9 billion and its earnings per share (EPS) guidance to $10.85. In a significant strategic move, Johnson & Johnson announced a $2 billion investment to expand its manufacturing presence in North Carolina. This investment will include a new 160,000+ square foot facility at FUJIFILM’s biopharmaceutical site in Holly Springs, creating approximately 120 new jobs. Additionally, Wolfe Research has raised its price target on Johnson & Johnson to $195 from $175, maintaining an Outperform rating. The firm’s decision is based on increased confidence in the company’s upcoming talc litigation outcome. These developments highlight Johnson & Johnson’s ongoing efforts to strengthen its market position and operational capabilities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.